VBI Vaccines (OTCPK:VBIV.Q) - Prezzo delle azioni, notizie e analisi

VBIV.Q Panoramica delle azioni

VBI Vaccines Inc. è un'azienda biofarmaceutica in fase commerciale che sviluppa e vende vaccini per il trattamento dell'immuno-oncologia e delle malattie infettive.

Informazioni sull'azienda

VBIV.Q analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	2/6
Dividendi	0/6

Premi

Analisi del rischio

Does not have a meaningful market cap ($14K)

Negative shareholders equity

Earnings have declined by 17.4% per year over past 5 years

Highly volatile share price over the past 3 months compared to the US market

+ 1 più rischio

VBI Vaccines Inc. Concorrenti

TRACON Pharmaceuticals

OTCPK:TCON

US$181.8k

ObsEva

OTCPK:OBSE.F

US$11.7k

Aridis Pharmaceuticals

OTCPK:ARDS

US$10.7k

Aditxt

NasdaqCM:ADTX

US$55.9k

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per VBI Vaccines
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$0.0005
Massimo di 52 settimane	US$1.35
Minimo di 52 settimane	US$0.0002
Beta	2.12
1Variazione di 1 mese	-95.45%
Variazione a 3 mesi	-99.62%
Variazione di 1 anno	-99.92%
3Variazione a 3 anni	-100.00%
Variazione a 5 anni	-100.00%
Variazione dall'IPO	-100.00%

Notizie e aggiornamenti recenti

Recent updates

VBI Vaccines down 10% on $300M mixed shelf offering; also ends two equity offerings

Aug 26

VBI Vaccines: Recent VBI-1901 Data Supports My Bull Thesis

Jun 17

Is VBI Vaccines (NASDAQ:VBIV) A Risky Investment?

Jun 09

Is VBI Vaccines (NASDAQ:VBIV) Using Debt Sensibly?

Jan 24

Rendimenti per gli azionisti

	VBIV.Q	US Biotechs	US Mercato
7D	0%	-0.7%	-1.6%
1Y	-99.9%	19.8%	30.8%

Ritorno vs Industria: VBIV.Q underperformed the US Biotechs industry which returned 19.8% over the past year.

Rendimento vs Mercato: VBIV.Q underperformed the US Market which returned 30.8% over the past year.

Volatilità dei prezzi

Is VBIV.Q's price volatile compared to industry and market?
VBIV.Q volatility
VBIV.Q Average Weekly Movement	58.1%
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	2.9%

Prezzo delle azioni stabile: VBIV.Q's share price has been volatile over the past 3 months compared to the US market.

Volatilità nel tempo: VBIV.Q's weekly volatility has increased from 33% to 58% over the past year.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
n/a	135	Jeff Baxter	www.vbivaccines.com

VBI Vaccines Inc. è un'azienda biofarmaceutica in fase commerciale che sviluppa e vende vaccini per il trattamento dell'immuno-oncologia e delle malattie infettive. Offre il vaccino contro l'epatite B (HBV) con i marchi PreHevbrio, PreHevbri e Sci-B-Vac. L'azienda sviluppa anche VBI-2601, un candidato immunoterapeutico a base di proteine per il trattamento dell'infezione cronica da HBV; VBI-1901, un candidato immunoterapeutico per il cancro del glioblastoma; VBI-1501, un candidato vaccino profilattico contro il citomegalovirus; e VBI-2501 per il trattamento del virus Zika.

VBI Vaccines Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di VBI Vaccines con la sua capitalizzazione di mercato?
VBIV.Q statistiche fondamentali
Capitalizzazione di mercato	US$14.34k
Guadagni(TTM)	-US$83.99m
Ricavi(TTM)	US$9.41m

0.0x

Rapporto P/S

0.0x

Rapporto P/E

VBIV.Q è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
VBIV.Q Conto economico (TTM)
Ricavi	US$9.41m
Costo del fatturato	US$11.67m
Profitto lordo	-US$2.26m
Altre spese	US$81.73m
Guadagni	-US$83.99m

Ultimi guadagni dichiarati

Mar 31, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-2.93
Margine lordo	-24.03%
Margine di profitto netto	-892.47%
Rapporto debito/patrimonio netto	-891.6%

Come si è comportato VBIV.Q nel lungo periodo?

Vedi performance storica e confronto

VBIV.Q Panoramica delle azioni

Premi

Analisi del rischio

VBI Vaccines Inc. Concorrenti

OTCPK:TCON

US$181.8k

OTCPK:OBSE.F

US$11.7k

OTCPK:ARDS

US$10.7k

NasdaqCM:ADTX

US$55.9k

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

The Nasdaq Stock Market to Delist Ordinary Shares of VBI Vaccines

VBI Vaccines Inc.(OTCPK:VBIV.Q) dropped from NASDAQ Composite Index

Nasdaq Determines to Delist Common Stock of VBI Vaccines in Accordance with Listing Rules 5101, 5110(b), and IM-5101-1

Nasdaq Provides Until July 8 Deadline to VBI Vaccines to Meet Minimum Stockholders' Equity Requirement

VBI Vaccines Inc. Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients

VBI Vaccines Inc. has filed a Follow-on Equity Offering in the amount of $8.468289 million.

Recent updates

The Nasdaq Stock Market to Delist Ordinary Shares of VBI Vaccines

VBI Vaccines Inc.(OTCPK:VBIV.Q) dropped from NASDAQ Composite Index

Nasdaq Determines to Delist Common Stock of VBI Vaccines in Accordance with Listing Rules 5101, 5110(b), and IM-5101-1

Nasdaq Provides Until July 8 Deadline to VBI Vaccines to Meet Minimum Stockholders' Equity Requirement

VBI Vaccines Inc. Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients

VBI Vaccines Inc. has filed a Follow-on Equity Offering in the amount of $8.468289 million.

VBI Vaccines Inc. has completed a Follow-on Equity Offering in the amount of $2.000001 million.

VBI Vaccines Inc. has filed a Follow-on Equity Offering in the amount of $2.000001 million.

VBI Vaccines Inc. Presents Encouraging Early Tumor Response Data from Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma

VBI Vaccines Inc. announced delayed annual 10-K filing

VBI Vaccines Inc. Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology Annual Meeting

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Inc. Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program

VBI Vaccines Inc. Announces Interim Data from the Phase 1 Clinical Study of its Multivalent Pan-Coronavirus Vaccine Candidate, VBI-2901

VBI Vaccines Inc. Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM

Consensus revenue estimates increase by 291%, EPS downgraded

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Inc. Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults

Consensus EPS estimates upgraded to US$4.46 loss

New major risk - Shareholder dilution

VBI Vaccines Inc. has completed a Follow-on Equity Offering in the amount of $18 million.

VBI Vaccines Inc. announced that it expects to receive $3 million in funding from Brii Biosciences Limited

VBI Vaccines Inc.(NasdaqCM:VBIV) dropped from Russell 2000 Dynamic Index

VBI Vaccines Inc. Announces Prehevbri® Is Now Available in the United Kingdom for the Prevention of Hepatitis B in Adults

Now 21% undervalued after recent price drop

Consensus revenue estimates decrease by 38%, EPS upgraded

Price target decreased by 45% to US$33.00

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 1,377%

Insufficient new directors

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B

VBI Vaccines Inc. Announces Health Canada Approval for Prehevbrio™ for Prevention of Hepatitis B in Adults

No longer forecast to breakeven

VBI Vaccines Presents Additional Phase 1/2A Data from VBI-1901 in Recurrent GBM At the 2022 Society for Neuro-Oncology Annual Meeting

Consensus forecasts updated

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Announces Initiation of Phase 1 Study of Multivalent Coronavirus Vaccine Candidate, VBI-2901

VBI Vaccines: Recent Updates Have Fortified My Long-Term Outlook

VBI Vaccines Inc. Announces Presentation of Physician-Initiated Compassionate Use Data of Its 3-Antigen Hepatitis B Vaccine At the 2022 International HBV Meeting

VBI Vaccines gets up to $100M debt funding from K2 HealthVentures

VBI Vaccines Inc. Announces the Resignation of Linda C. Bain from the Board of Directors

Valneva, VBI Vaccines in pact to launch Hep B vaccine in Europe

VBI Vaccines down 10% on $300M mixed shelf offering; also ends two equity offerings

Consensus revenue estimates fall by 32%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Inc. Announces Appointment of John Dillman as Chief Commercial Officer

VBI Vaccines Receives Non-Compliance Notice from Nasdaq

VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for Its 3-Antigen Adult Hepatitis B Vaccine

VBI Vaccines Inc. Receives U.S. Food and Drug Administration Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma

VBI Vaccines: Recent VBI-1901 Data Supports My Bull Thesis

Is VBI Vaccines (NASDAQ:VBIV) A Risky Investment?

VBI Vaccines Inc. Announces Updated Phase 2A Tumor Response and Overall Survival Data for VBI-1901

VBI Vaccines Inc. Announces UK MHRA Marketing Authorisation for Prehevbri

Consensus forecasts updated

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat